---
schema_version: "secwatch.filing_event.v1"
accession: "0001420720-26-000014"
form_type: "8-K"
ticker: "IBIO"
cik: "0001420720"
company_name: "iBio, Inc."
filed_at: "2026-08-04T11:05:35+00:00"
generated_at: "2026-08-04T11:10:21.198857+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# iBio appoints Molly Carr as CMO; grants 430,000 stock options at $1.40/share

## Summary
- Dr. Carr appointed CMO effective July 31, 2026, leading global clinical strategy for obesity and cardiometabolic pipeline.
- She previously served as Clinical Head at Eli Lilly, overseeing insulin/glucagon portfolio including Phase 3 efsitora.
- Employment terms: $470,000 base salary, 40% target bonus, severance provisions.
- Inducement award: options to purchase 430,000 shares at $1.40, vesting 25% after one year then monthly over 3 years.
- Company advancing IBIO-600 and IBIO-610 into next clinical phases.

## SEC filing metadata
- accession: 0001420720-26-000014
- form_type: 8-K
- ticker: IBIO
- cik: 0001420720
- company_name: iBio, Inc.
- filed_at: 2026-08-04T11:05:35+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420720/000142072026000014/0001420720-26-000014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420720/000142072026000014/ibio-20260722x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001420720-26-000014
- JSON: https://secwatch.observer/filing/0001420720-26-000014.json
- Plain text: https://secwatch.observer/filing/0001420720-26-000014.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.